Sun Pharmaceutical Industries Q1 Results FY27: Uniresearch Predictions, Analyst Views and Key Watchpoints

The Sun Pharmaceutical Industries Q1 Results FY27 outlook is anchored on Q4 FY26 verified actuals and Uniresearch analysis applying the 34-analyst FY27 consensus to Q1 FY26 verified actuals. Uniresearch projects Revenue Rs 15,499 Cr (+11.9% YoY) and PAT Rs 2,651 Cr (+15.6% YoY). Prepared by Ankit Jaiswal.

Click Here – Get Free Investment Predictions

Sun Pharmaceutical Industries Q1 Results FY27 – Uniresearch Prediction

Metric	Q1 FY26 Actual	Q1 FY27 Uniresearch Prediction	YoY Change	Source
Sun Pharmaceutical Industries Revenue (Rs Cr)	13,851	15,499	+11.9%	Uniresearch | 34-analyst consensus applied to Q1 FY26 verified actual
PAT (Rs Cr)	2,293	2,651	+15.6%	Uniresearch | 34-analyst consensus applied to Q1 FY26 verified actual
Avg Analyst Target	Rs 2,040	12-month view	–	Analyst consensus (34 analysts)

Predictions apply 34-analyst FY27 consensus (Rev +11.9%, PAT +15.6%) to Q1 FY26 verified actuals. Not guaranteed outcomes.

Sun Pharmaceutical Industries Q4 FY26 Key Metrics – Baseline for Sun Pharmaceutical Industries Q1 Results FY27

Metric	Q4 FY26 Actual	YoY Change	Source
Revenue (Rs Cr)	14,612	+12.8% YoY	Consolidated quarterly financial data
PAT (Rs Cr)	2,710	+25.8% YoY	Consolidated quarterly financial data

What Analysts Are Saying About Sun Pharmaceutical Industries Q1 Results FY27

Across 34 analysts covering Sun Pharmaceutical Industries, the FY27 consensus projects revenue growth of +11.9% and profit growth of +15.6%, with an average 12-month price target of Rs 2,040. The Sun Pharmaceutical Industries prediction reflects this consensus applied to verified Q1 FY26 actuals.

Key Watchpoints for Sun Pharmaceutical Industries

Revenue Delivery Against Consensus

Whether Sun Pharmaceutical Industries delivers Revenue Rs 15,499 Cr (+11.9% consensus growth) in Q1 Results FY27 is the primary watchpoint. Q1 FY26 base was Rs 13,851 Cr.

PAT Performance in Q1 FY27

Whether Sun Pharmaceutical Industries achieves PAT Rs 2,651 Cr (+15.6% growth from Q1 FY26 base of Rs 2,293 Cr) is the second major metric. Q4 FY26 PAT was Rs 2,710 Cr.

Risks to the Sun Pharmaceutical Industries Prediction

Below-Consensus Revenue Growth

If Revenue comes in below the +11.9% consensus estimate, actual revenue would fall short of the Rs 15,499 Cr target.

PAT Pressure

The PAT prediction of Rs 2,651 Cr could face pressure from cost factors not captured in the 34-analyst consensus of +15.6%.

Conclusion: Sun Pharmaceutical Industries

The Sun Pharmaceutical Industries Uniresearch prediction of Revenue Rs 15,499 Cr and PAT Rs 2,651 Cr is derived from the 34-analyst FY27 consensus applied to verified Q1 FY26 actuals. Track live updates and analyst calls on Univest.

Track Sun Pharmaceutical Industries Live on the Univest Screener

Download the Univest iOS App or Univest Android App for live Q1 Results FY27 alerts.

Frequently Asked Questions on Sun Pharmaceutical Industries

What is Uniresearch’s PAT prediction for Sun Pharmaceutical Industries Q1 Results FY27?

Ans. Uniresearch projects Sun Pharmaceutical Industries PAT at Rs 2,651 Cr, applying 34-analyst FY27 profit growth consensus of +15.6% to Q1 FY26 verified PAT of Rs 2,293 Cr.

What is the Revenue prediction for Sun Pharmaceutical Industries Q1 Results FY27?

Ans. Sun Pharmaceutical Industries Revenue is projected at Rs 15,499 Cr, applying +11.9% FY27 revenue consensus to Q1 FY26 base of Rs 13,851 Cr.

What were Sun Pharmaceutical Industries Q1 Results FY27?

Ans. Q4 FY26 consolidated Revenue was Rs 14,612 Cr (+12.8% YoY) and PAT was Rs 2,710 Cr (+25.8% YoY).

How many analysts cover Sun Pharmaceutical Industries Q1 Results FY27?

Ans. The Sun Pharmaceutical Industries prediction is based on the consensus of 34 analysts with an average 12-month price target of Rs 2,040.

What is the FY27 growth consensus used in the Sun Pharmaceutical Industries Q1 Results FY27 prediction?

Ans. The FY27 consensus used is revenue growth of +11.9% and profit growth of +15.6%, based on 34 analyst calls.

What are the risks to the Sun Pharmaceutical Industries Q1 Results FY27?

Ans. Key risks include below-consensus revenue growth (target: +11.9%) and unexpected cost pressures impacting the +15.6% PAT consensus.

What is the Q1 FY26 base for the Sun Pharmaceutical Industries Q1 Results FY27?

Ans. Q1 FY26 consolidated Revenue was Rs 13,851 Cr and PAT was Rs 2,293 Cr, the base for the Sun Pharmaceutical Industries Uniresearch prediction.